Quartz·1 min read·medium

FDA approved Replimune's melanoma treatment after rejecting it twice

Cris Tolomia
AI Summary

The FDA has granted approval to Replimune's engineered viral therapy for melanoma. This decision follows two previous rejections based on concerns regarding the design of the company's clinical trials.

The agency had twice rejected the engineered viral therapy over concerns about the design of Replimune's clinical trial

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthbusiness

Get the full story

Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.

Create free account

Already have an account? Sign in

FDA approved Replimune's melanoma treatment after rejecting it twice — Headlinne — headlinne